---

Brought to you by RivalSense - an AI tool for monitoring any company.

RivalSense tracks the most important product launches, fundraising news, partnerships, hiring activities, pricing changes, tech news, vendors, corporate filings, media mentions, and other developments of companies you're following 💡

---

LongeVC

🌎 longevc.com

LongeVC is a venture capital firm based in Lugano, Switzerland, founded in 2016. The company specializes in supporting early-stage biotech and longevity-focused founders, helping them gain industrial momentum, raise capital, and shape the future of the biotech industry. LongeVC aims to build a broad community of biotech innovators by funding companies in complementary sectors and facilitating collaboration among them.

---

LongeVC - Latest News and Updates

• LongeVC has invested in Glyphic Biotechnologies, which is developing single-molecule protein sequencing technology.
• LongeVC's comparative indices for 2023 show slight improvements in net turnover, profit or loss, equity capital, fixed assets, balance, tangible assets, and liquidity.
• Sergey Jakimov, co-founder of LongeVC, emphasizes the company's focus on investing in innovative biotech and healthcare solutions to improve health spans and support early-stage companies in longevity science.
• Krishna Amin has joined LongeVC as a Venture Scout.
• LongeVC's portfolio company Longenesis has partnered with Novartis Baltics and Daugavpils Regional Hospital to launch a pilot project for cardiovascular disease treatment and prevention in Latvia.

• LongeVC partner Sergey Jakimov posed a challenging question on the LEVITY podcast about prioritizing aging solutions over immediate cancer patient needs.
• Artemy Shumskiy from LongeVC participated in a panel discussing the impact of the EU’s AI Act on life sciences innovation, funding, and partnerships.

---

Sign up to receive regular updates

If you liked the insights, consider following your own companies of interest. Receive weekly insights directly to your inbox using RivalSense.